Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Switzerland / NCT06150066
Active, not recruiting Observational

The Effect of Smoking on Peri-implantitis

NCT06150066 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Mustafa Kemal University
Phase
Observational
Started
2023-11-21
Last updated
2025-07-20

Condition(s) studied

PeriimplantitisMicrobial ColonizationCytokines

Investigational drug(s) / intervention(s)

Recruiting samples

Recruiting samples: The GCF, plaque, and saliva samples will recruited from participants.

Study summary

the primary aim of this project is to evaluate the microbiological and inflammatory effect of smoking status and smoking severity on periimplantitis lesions. The secondary aim is to compare the effect of smoking on periimplantitis and periodontal microbiota and inflammation in the same individuals.

There will include 96 patients, equally divided into four groups: Smokers with peri-implantitis (n=24), non-smoker individuals with peri-implantitis (n=24), smokers with healthy peri-implant tissues (n=24), non-smoker individuals with healthy peri-implant tissues (n=24).

Microbiological and biochemical analyses will be performed on the samples taken.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
Accepted
The inclusion criteria for study groups: * 18 years old * Body mass index (BMI) £30 kg/m * Presence of min 1 implant and 1 tooth for the implant groups * At least 1 year of implant loading for implant groups for the implant groups Exclusion criteria for study groups: * Systemic diseases such as diabetes mellitus, hepatic or renal disease, or other medical conditions or transmittable diseases (ASA score III, IV, V) * Pregnancy * Having undergone antibiotics in the previous 6 months * Periodontal treatment in the previous 6 months

Primary outcome measure(s)

  • The evaluation of the abundance of Fusobacterium nucleatum — 2 months
    The presence and abundance of Fusobacterium nucleatum will be analysed by real-time Q-PCR in plaque samples
  • The evaluation of the abundance of Campylobacter rectus in plaque samples — 2 months
    The presence and abundance of Campylobacter rectus will be analysed by real-time Q-PCR in plaque samples
  • The evaluation of the abundance of Prevotella intermedia in plaque samples — 2 months
    The presence and abundance of Prevotella intermedia will be analysed by real-time Q-PCR in plaque samplse
  • The evaluation of the abundance of Aggregatinacter actinomycetemcomitans in plaque samples — 2 months
    The presence and abundance of Aggregatinacter actinomycetemcomitans will be analysed by real-time Q-PCR in plaque samples
  • The evaluation of the abundance of Porphyromonas gingivalis in plaque samples — 2 months
    The presence and abundance of Porphyromonas gingivalis will be analysed by real-time Q-PCR in plaque samples
  • The evaluation of the abundance of Tannerella forsythia in plaque samples — 2 months
    The presence and abundance of Tannerella forsythia will be analysed by real-time Q-PCR in plaque samples
  • The evaluation of the abundance of Treponema denticola in plaque samples — 2 months
    The presence and abundance of Treponema denticola will be analysed by real-time Q-PCR in plaque samples
  • The evaluation of the abundance of Saccharibacteria (TM7) in plaque samples — 2 months
    The presence and abundance of Saccharibacteria (TM7) will be analyzed by real-time Q-PCR in plaque samplse
  • The evaluation of the abundance of Streptococcus aureus in plaque samples — 2 months
    The presence and abundance of Streptococcus aureus will be analysed by real-time Q-PCR in plaque samples
  • The evaluation of the abundance of Actinomyces oris in plaque samples — 2 months
    The presence and abundance of Actinomyces oris will be analysed by real-time Q-PCR in plaque samples

Trial sites (2)

FacilityCityRegionStatus
University of Bern Bern Switzerland
Hatay Mustafa Kemal University Antakya Hatay

Other trials for the same condition

Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery Recruiting
Bern Birth Cohort / Trajectory of Microbiota Maturation in Healthy Bern Infants - a Network Approach Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06150066 on ClinicalTrials.gov ↗ ← All trials in Switzerland